IRVINE, Calif., July 7, 2006 (PRIMEZONE) -- "A recent Wall Street Journal report (6/22) has thrust the spotlight on an issue for which some publicly traded business plans are based: safety in vascular stents," stated SmallCap Sentinel analyst D.R. Clark. "The potent megaphone that is the Wall Street Journal outlines in a recent article the growing evidence that the newest generations of drug-coated vascular stents are associated with potentially fatal safety concerns and long term complications."
"Smaller stent manufacturers have been mindful of these concerns and have been crafting and developing biotechnology to abate these issues," Clark added. "MIV Therapeutics (OTCBB:MIVT), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, has announced that a growing body of evidence validates MIV's core technology to make a safer type of coronary stents based on proprietary bio-friendly stent coatings."
The informational report "The Silver Tsunami: Baby Boomers & Biotech Breakthroughs" is available at www.SmallCapSentinel.com and will address stents and stent related companies including MIV Therapeutics, Inc. (OTCBB:MIVT), Angiotech Pharmaceuticals Inc. (Nasdaq:ANPI), Conor Medsystems Inc. (Nasdaq:CONR), and Boston Scientific CP (NYSE:BSX). The report will place specific emphasis on drug eluting stents, their design, application, and imperative need.
Interested parties may view additional information about MIVT via this direct link: http://www.trilogy-capital.com/autoir/mivt_autoir.html
Individuals may also register to receive free future reports at: http://stockupticks.com/register.html
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that affect results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project capabilities, intent, resources, or experience.
All information contained herein is based upon sources believed to be reliable but no representation is made as to its accuracy or completeness. This report is neither a solicitation to buy nor an offer to sell securities but is rather a paid advertisement provided for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid fifteen hundred dollars by MIV Therapeutics Corp. for preparation and distribution of this report and other advertising services. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject companies.